Therapeutics: T-cell immunoreceptor with Ig and ITIM domains (TIGIT)

Cancer

INDICATION: Cancer

Studies in human tissue samples and mice suggest combined blockade of the PD-L1 and TIGIT

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE